Clinical Trial

Observational, Bi-directional (Prospective and Retrospective) Study for Patients With Newly Diagnosed Ovarian Cancer Stages IA to IVB, or Persistent or Recurrent Disease From January 2021; Irrespective of Histology

Study acronym: OLIVIA
Recruiting
View on ClinicalTrials.gov →
Summary
The findings from this study have the potential to serve as a foundation for evaluating the current practices related to surgical procedures, systemic therapies, hyperthermic intraperitoneal chemotherapy, and referrals to geneticists for OC patients. By identifying the strengths and weaknesses of the existing care, this project intends to generate valuable insights that can lead to the implementation of quality parameters for the treatment of ovarian cancer in the country.
Protocol Amendment History 5 changes
notable Trial sites reduced: 18 -> 15 locations 2026-08-05
notable Trial sites expanded: 13 -> 18 locations 2026-06-30
notable Trial sites expanded: 1 -> 13 locations 2026-05-29
notable Primary completion pushed: 2026-03-31 -> 2027-06-30 2026-04-30
minor Completion pushed: 2026-03-31 -> 2027-06-30 2026-04-30
Trial Details
NCT Number NCT07167433
Lead Sponsor AstraZeneca
Conditions Ovarian Cancer
Enrollment 250 participants
Start Date 2025-09-19
Primary Completion 2027-06-30 (estimated)
Study Completion 2027-06-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-04